EXEL
Price
$44.08
Change
+$0.41 (+0.94%)
Updated
Jun 30 closing price
Capitalization
12.02B
42 days until earnings call
INNMF
Price
$0.18
Change
+$0.07 (+63.64%)
Updated
Jun 27 closing price
Capitalization
55.67M
Interact to see
Advertisement

EXEL vs INNMF

Header iconEXEL vs INNMF Comparison
Open Charts EXEL vs INNMFBanner chart's image
Exelixis
Price$44.08
Change+$0.41 (+0.94%)
Volume$3.43M
Capitalization12.02B
Amplia Therapeutics
Price$0.18
Change+$0.07 (+63.64%)
Volume$52.73K
Capitalization55.67M
EXEL vs INNMF Comparison Chart in %
Loading...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INNMF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXEL vs. INNMF commentary
Jul 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a Buy and INNMF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 01, 2025
Stock price -- (EXEL: $43.67 vs. INNMF: $0.18)
Brand notoriety: EXEL: Notable vs. INNMF: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EXEL: 102% vs. INNMF: 136%
Market capitalization -- EXEL: $12.02B vs. INNMF: $50.66M
EXEL [@Biotechnology] is valued at $12.02B. INNMF’s [@Biotechnology] market capitalization is $50.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXEL’s FA Score shows that 2 FA rating(s) are green whileINNMF’s FA Score has 0 green FA rating(s).

  • EXEL’s FA Score: 2 green, 3 red.
  • INNMF’s FA Score: 0 green, 5 red.
According to our system of comparison, EXEL is a better buy in the long-term than INNMF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXEL’s TA Score shows that 3 TA indicator(s) are bullish while INNMF’s TA Score has 4 bullish TA indicator(s).

  • EXEL’s TA Score: 3 bullish, 3 bearish.
  • INNMF’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both EXEL and INNMF are a good buy in the short-term.

Price Growth

EXEL (@Biotechnology) experienced а +8.17% price change this week, while INNMF (@Biotechnology) price change was +61.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +32.93%, and the average quarterly price growth was +6.81%.

Reported Earning Dates

EXEL is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXEL($12B) has a higher market cap than INNMF($55.7M). INNMF YTD gains are higher at: 330.508 vs. EXEL (31.141). EXEL has higher annual earnings (EBITDA): 844M vs. INNMF (-6.43M). EXEL has more cash in the bank: 1.03B vs. INNMF (10.9M). INNMF has less debt than EXEL: INNMF (13.9K) vs EXEL (187M).
EXELINNMFEXEL / INNMF
Capitalization12B55.7M21,544%
EBITDA844M-6.43M-13,125%
Gain YTD31.141330.5089%
P/E Ratio20.13N/A-
Revenue2.3BN/A-
Total Cash1.03B10.9M9,459%
Total Debt187M13.9K1,345,324%
FUNDAMENTALS RATINGS
EXEL vs INNMF: Fundamental Ratings
EXEL
INNMF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
49
Fair valued
PROFIT vs RISK RATING
1..100
2580
SMR RATING
1..100
3297
PRICE GROWTH RATING
1..100
4034
P/E GROWTH RATING
1..100
92100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INNMF's Valuation (49) in the null industry is in the same range as EXEL (73) in the Biotechnology industry. This means that INNMF’s stock grew similarly to EXEL’s over the last 12 months.

EXEL's Profit vs Risk Rating (25) in the Biotechnology industry is somewhat better than the same rating for INNMF (80) in the null industry. This means that EXEL’s stock grew somewhat faster than INNMF’s over the last 12 months.

EXEL's SMR Rating (32) in the Biotechnology industry is somewhat better than the same rating for INNMF (97) in the null industry. This means that EXEL’s stock grew somewhat faster than INNMF’s over the last 12 months.

INNMF's Price Growth Rating (34) in the null industry is in the same range as EXEL (40) in the Biotechnology industry. This means that INNMF’s stock grew similarly to EXEL’s over the last 12 months.

EXEL's P/E Growth Rating (92) in the Biotechnology industry is in the same range as INNMF (100) in the null industry. This means that EXEL’s stock grew similarly to INNMF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXELINNMF
RSI
ODDS (%)
Bearish Trend 4 days ago
64%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
89%
Momentum
ODDS (%)
Bullish Trend 4 days ago
67%
Bullish Trend 4 days ago
80%
MACD
ODDS (%)
Bullish Trend 4 days ago
70%
N/A
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
66%
Bullish Trend 4 days ago
71%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
66%
Bullish Trend 4 days ago
73%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 5 days ago
63%
Bearish Trend 5 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
62%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 4 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INNMF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GOFPY11.490.04
+0.31%
Greek Organisation of Football Prognostics SA
PHCCF6.28N/A
N/A
PHC Holdings Corp.
DSNKY22.88-0.08
-0.35%
Daiichi Sankyo Co., Ltd.
SRCRF0.15N/A
-0.76%
Scorpio Gold Corp.
ACHFF1.36-0.02
-1.45%
Arch Biopartners Inc.

EXEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with JAZZ. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then JAZZ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+1.35%
JAZZ - EXEL
36%
Loosely correlated
-0.57%
RIGL - EXEL
29%
Poorly correlated
+3.73%
RVMD - EXEL
28%
Poorly correlated
-1.52%
CGON - EXEL
28%
Poorly correlated
-0.46%
UTHR - EXEL
28%
Poorly correlated
N/A
More

INNMF and

Correlation & Price change

A.I.dvisor tells us that INNMF and CGEN have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INNMF and CGEN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INNMF
1D Price
Change %
INNMF100%
+61.64%
CGEN - INNMF
24%
Poorly correlated
-1.78%
HOFBF - INNMF
22%
Poorly correlated
N/A
EXEL - INNMF
21%
Poorly correlated
+1.35%
ARMP - INNMF
21%
Poorly correlated
+4.71%
KRRO - INNMF
20%
Poorly correlated
-3.16%
More